# Glaukos Reports Positive Three-Year Phase 3 Extension Data for Epioxa

- URL: https://stocks.freetheai.org/news/glaukos-reports-positive-three-year-phase-3-extension-data-for-epioxa-39dfd8
- Published: 2026-10-07T20:05:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NYSE:GKOS](https://stocks.freetheai.org/symbols/NYSE-GKOS)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Glaukos Corporation (GKOS) announced positive long-term results from a three-year Phase 3 extension study evaluating Epioxa, its single-dose treatment for the eye condition keratoconus. The data showed a sustained 1.9D Kmax improvement at the three-year mark, with no serious adverse events reported in the treated eyes. Additionally, 92% of the patients completed their third-year follow-up visit. The study also revealed that 29% of treated eyes gained two or more lines of best corrected visual acuity, while 20% achieved an improvement of three or more lines.

These long-term findings confirm the durable efficacy and safety of Epioxa from a single treatment session. By demonstrating long-lasting vision improvement without the need for additional interventions, the treatment could offer a highly favorable economic profile for clinics and patients alike. The absence of serious side effects over three years significantly reduces the risks associated with long-term use, which is expected to support clinician adoption, patient demand, and insurance reimbursement. Following the announcement, Glaukos Corp shares rose 6.59% to 172.2 USD.

Moving forward, the focus turns to the ongoing commercialization efforts for Epioxa. Investors and healthcare providers should monitor potential catalysts such as larger real-world data releases, updated clinical guidelines, and new reimbursement approvals, which could further drive revenue growth for the company.

## Key points

- Glaukos Corporation reported positive three-year Phase 3 extension data for its keratoconus treatment Epioxa.
- Treated eyes showed a sustained 1.9D Kmax improvement at three years after a single treatment.
- No serious adverse events were reported in treated eyes over the three-year period.
- Visual acuity improved, with 29% of eyes gaining two or more lines and 20% gaining three or more lines.
- The high study completion rate of 92% at year three reinforces confidence in the long-term findings.

## Questions and answers

### What is Epioxa used to treat?

Epioxa is a single-treatment therapy developed by Glaukos Corporation to treat keratoconus, an eye condition.

### What did the three-year Epioxa study show?

The study showed a sustained 1.9D Kmax improvement, meaningful vision gains, and no serious adverse events after three years.

### How did Glaukos stock react to the news?

Glaukos Corp shares increased by 6.59% to 172.2 USD following the release of the three-year clinical trial results.